Diane’s farewell message
After 52 years at WAMU, Diane Rehm says goodbye.
The new class of weight-loss drugs including Ozempic, Wegovy, Mounjaro and Zepbound have revolutionized the treatment of obesity.
Last week, the FDA approved a medication said to be the most potent yet in the treatment of chronic obesity, a condition that affects more than 100 million American adults.
Developed by Eli Lilly, Zepbound is the latest in a new class of drugs doctors now have to help patients lose weight. Others include Ozempic, Wegovy, and Mounjaro.
“It’s like this total new world for weight control,” says Gina Kolata, a reporter for the New York Times. She has written about the issue of obesity for decades and adds, “These medications are really changing things. They are completely changing perspectives for people with obesity.”
Kolata joins Diane on the latest episode of On My Mind to break down how these drugs work, possible side effects, and what’s next in the development of obesity medications.
Guests
- Gina Kolata Health reporter at The New York Times
Most Recent Shows
Reflections on 100 days of the Trump administration
Diane takes the mic one last time at WAMU. She talks to Susan Page of USA Today about Trump’s first hundred days – and what they say about the next hundred.
Rep. Jamie Raskin on countering “MAGA chaos”
Maryland Congressman Jamie Raskin was first elected to the House in 2016, just as Donald Trump ascended to the presidency for the first time. Since then, few Democrats have worked as…
How deportations ignited a clash between the White House and the courts
Can the courts act as a check on the Trump administration’s power? CNN chief Supreme Court analyst Joan Biskupic on how the clash over deportations is testing the judiciary.